Subscap Reverse Shoulder Arthroplasty
Launched by UNIVERSITY OF MARYLAND, BALTIMORE · Apr 18, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of repairing a specific shoulder tendon called the subscapularis during a procedure known as reverse shoulder arthroplasty. This surgery is often performed for shoulder injuries, including problems with the rotator cuff. Researchers want to find out if fixing this tendon can help patients recover better or if it might cause issues with movement afterward. They are also looking into whether repairing the tendon can reduce the risk of dislocation, which is a rare but concerning complication after surgery. The trial will involve 148 patients, and participants will need to attend follow-up appointments at various points after their surgery for up to two years.
To be eligible for this study, participants must be between 18 and 95 years old and planning to undergo reverse shoulder surgery. However, those with certain conditions, like an irreparable subscapularis tendon or specific types of shoulder fractures, will not be able to participate. It's important to note that joining this study is voluntary, and while there may not be direct benefits from participation, the information gained could help improve future treatments for shoulder injuries. Participants won't have to pay anything to take part in the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. 18 to 95 years old
- • 2. Undergoing reverse shoulder arthroplasty for any indication including revision surgery
- Exclusion Criteria:
- • 1. Irreparable Subscapularis Tendon
- • a. Reparability of Subscapularis will be determined based on MRI or CT scan obtained preoperatively and confirmed intraoperatively. Tendons must be intact with less than Grade I or II Fatty Infiltration as determined by the Goutallier classification.
- • 2. Any history of proximal humerus fracture
- • 3. Any revision with proximal humerus bone loss
About University Of Maryland, Baltimore
The University of Maryland, Baltimore (UMB) is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, UMB leverages its extensive resources and expertise across various disciplines, including medicine, pharmacy, nursing, and social work, to contribute to groundbreaking discoveries and improve patient outcomes. Committed to ethical research practices and collaboration, UMB fosters an environment that promotes the translation of scientific knowledge into real-world applications, ultimately enhancing the well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Mohit Gilotra, MD
Principal Investigator
University of Maryland, Baltimore
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials